Currently, peroxisome proliferator-activated receptor (PPAR) agonists are widely deployed as frontline agents for glycemic regulation due to their substantial insulin-sensitizing properties, which effectively decelerate diabetes progression [8]. This evidence concerns the gene INS and diabetes mellitus.